{"id":"NCT00472303","sponsor":"Grünenthal GmbH","briefTitle":"A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine","officialTitle":"A Randomized Withdrawal, Active- and Placebo-controlled, Double-blind, Multi-center Phase III Trial Assessing Safety and Efficacy of Oral CG5503 (Tapentadol) PR* in Subjects With Moderate to Severe Chronic Malignant Tumor-related Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07","primaryCompletion":"2012-06","completion":"2012-06","firstPosted":"2007-05-11","resultsPosted":"2014-05-07","lastUpdate":"2019-11-04"},"enrollment":622,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Tumor","Pain"],"interventions":[{"type":"DRUG","name":"Tapentadol Extended Release","otherNames":["Palexia","Nucynta","Yantil"]},{"type":"DRUG","name":"Matching Placebo after Tapentadol in the Titration Phase.","otherNames":[]},{"type":"DRUG","name":"Morphine Sulphate Controlled Release","otherNames":["MST® CONTINUS®"]}],"arms":[{"label":"Matching Placebo after Tapentadol in Titration Phase","type":"PLACEBO_COMPARATOR"},{"label":"Morphine Controlled Release","type":"ACTIVE_COMPARATOR"},{"label":"Tapentadol Prolonged Release","type":"EXPERIMENTAL"}],"summary":"The purpose of this study will be to determine whether tapentadol (CG5503) is effective and safe in the treatment of chronic tumor related pain compared to placebo. In addition tapentadol (CG5503) will also be compared to morphine controlled release, also referred to as slow release (SR).\n\n\\*Tapentadol prolonged-release (PR) is the term used in the European Union and is referred to as extended release (ER) in the United States.","primaryOutcome":{"measure":"Number of Participants Scored as Responder in Maintenance Phase.","timeFrame":"Day 18 through Day 43 (End of Maintenance Phase)","effectByArm":[{"arm":"Tapentadol Prolonged Release (Maintenance Phase)","deltaMin":65,"sd":null},{"arm":"Morphine Controlled Release (Maintenance Phase)","deltaMin":75,"sd":null},{"arm":"Matching Placebo After Tapentadol in Titration Phase","deltaMin":55,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":null},"locations":{"siteCount":71,"countries":["Austria","Bulgaria","Croatia","Czechia","France","Germany","Hungary","Italy","Moldova","Poland","Romania","Russia","Serbia","Slovakia","Spain","Sweden"]},"refs":{"pmids":["25054392","27062079"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":25,"n":338},"commonTop":["Nausea","Constipation","Vomiting","Dizziness","Somnolence"]}}